Novo Nordisk

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

6 Stories Indexed

Last Updated: Just Now

Verified Entity Intelligence

World Politics & Diplomacy 03 Oct 2026, 10:33 PM IST

UN Says World Food Prices Near Four-Year High as Sugar and Cereal Costs Climb

Global food prices edged higher in September, approaching their highest level in nearly four years, according to the United Nations Food and Agriculture Organization. The increase was driven by firmer prices for sugar, cereals and vegetable oils, underscoring renewed pressure on import-dependent economies and households already strained by persistent inflation.

By RDU Global Wire5 min read

Global Markets & EquitiesJust now (11:45 AM IST)

Lilly’s Full Retatrutide Data Raises the Stakes in the Next Obesity Drug Race

Eli Lilly has released full phase 3 data on retatrutide, intensifying competition in the fast-growing obesity drug market and reinforcing investor focus on next-generation weight-loss therapies. The results add to a broader pipeline battle that is increasingly centered on efficacy, durability, and potential benefits beyond weight reduction.

5 min readRead →

Global Economy & Central BanksJust now (06:49 AM IST)

Two Indian Nationals Charged in U.S. Over Alleged Counterfeit Ozempic Smuggling From China

U.S. prosecutors in Florida have charged two Indian nationals in connection with an alleged scheme to smuggle counterfeit Ozempic into the United States from China, according to the Justice Department. The case lands amid surging American demand for GLP-1 drugs used for weight loss, intensifying pressure on regulators and law enforcement to police a fast-growing and lucrative gray market.

5 min readRead →

Global Health & Biotech10 Oct 2026, 08:15 PM IST

Weight-Loss Drugs Show Early Signs of Slowing Aging, as Frontier Tech Bets Expand Beyond Obesity

Drugmakers are increasingly pointing to evidence that popular GLP-1 weight-loss medicines may do more than reduce body weight: they could also influence biological aging pathways and lower the risk of age-related disease. The claims remain early and scientifically contested, but they are already reshaping investor expectations across biotech, longevity research, and adjacent frontier technology markets.

6 min readRead →

Global Markets & EquitiesJust now (03:47 AM IST)

Eli Lilly’s Triple-G Obesity Drug Posts Strong Early Weight Loss Even at Lowest Dose

Eli Lilly said its closely watched obesity candidate retatrutide produced substantial weight loss in a mid-stage trial, with patients on the lowest dose losing 12.7% of body weight. The result reinforces investor expectations that next-generation incretin therapies could extend the market beyond current GLP-1 leaders and intensify competition across global healthcare equities.

5 min readRead →

Global Markets & EquitiesJust now (09:54 AM IST)

Lilly’s Latest Weight-Loss Drug Drives Up to 60-Pound Loss in Diabetes Trial

Eli Lilly said its experimental triple-agonist drug retatrutide produced striking weight loss and meaningful blood-sugar improvements in people with type 2 diabetes, adding to the company’s lead in the fast-expanding obesity and metabolic disease market. The results intensify investor focus on a drug class that could reshape treatment standards and expand the commercial race against rival therapies.

5 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Novo Nordisk:

Washington, D.C.(1)U.S. Department of Justice(1)United States(1)Two Indian nationals(1)Global(1)Food and Agriculture Organization(1)